Literature DB >> 15014573

A Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine.

Donald P. Hay1, Daniel J. Hurley, Hillary C. McGuire, Linda K. Hay.   

Abstract

Primary care practitioners are in an ideal position to initiate treatment for patients with behavior, mood, and thought disturbances. It is believed that early identification and treatment of these symptomatic features of primary or secondary central nervous system disorders may significantly reduce morbidity and benefit the patient, his/her family, and involved caregivers, including the primary care physician. A broad list of central nervous system-active medications are utilized by family physicians to treat patients who exhibit symptoms of agitation, altered mood, and disordered thought. Some medications have demonstrated superiority over placebo or active medicines in reported clinical trials. This article is a brief overview of the safety and efficacy from reported studies of the use of medications frequently used to treat symptoms related to behavior, mood, and thought disturbances, with a specific focus on the clinical applicability of olanzapine.

Entities:  

Year:  2001        PMID: 15014573      PMCID: PMC181215          DOI: 10.4088/pcc.v03n0502

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  63 in total

1.  Diabetic ketoacidosis with olanzapine treatment.

Authors:  B Gatta; V Rigalleau; H Gin
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

2.  Placebo-controlled study of divalproex sodium for agitation in dementia.

Authors:  A P Porsteinsson; P N Tariot; R Erb; C Cox; E Smith; L Jakimovich; J Noviasky; N Kowalski; C J Holt; C Irvine
Journal:  Am J Geriatr Psychiatry       Date:  2001       Impact factor: 4.105

3.  Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.

Authors:  B J Kinon; S M Roychowdhury; D R Milton; A L Hill
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

4.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

Review 5.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

6.  Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.

Authors:  C M Beasley; M A Dellva; R N Tamura; H Morgenstern; W M Glazer; K Ferguson; G D Tollefson
Journal:  Br J Psychiatry       Date:  1999-01       Impact factor: 9.319

7.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Authors:  M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-09

8.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

Authors:  J S Street; W S Clark; K S Gannon; J L Cummings; F P Bymaster; R N Tamura; S J Mitan; D L Kadam; T M Sanger; P D Feldman; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-10

Review 9.  Treatment of schizophrenia and delusional disorder in the elderly.

Authors:  J H Eastham; D V Jeste
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

10.  Agitation in the demented elderly: a role for benzodiazepines?

Authors:  R J Ancill; W W Carlyle; R A Liang; S G Holliday
Journal:  Int Clin Psychopharmacol       Date:  1991       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.